Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)

NCT07319910 | Unknown

• 1 other identifier: EF-54
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel. The purpose of the program is to allow eligible patients to have access to TTFields while the NovoTTF-200T system is under FDA review. Safety and device performance will be monitored during routine clinical care.

Conditions

Locally Advanced Pancreatic Adenocarcinoma

Interventions

Nab paclitaxel DRUG

per standard of care

TTFields DEVICE

TTFields is a non-invasive locoregional therapy that uses alternating electric fields. TTFields are delivered to the abdomen though adhesive transducer arrays connected to the NovoTTF-200T system.

Gemcitabine DRUG

per standard of care

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 22 years
• Histologically or cytologically confirmed de novo pancreatic adenocarcinoma
• Locally advanced, non-metastatic disease
• ECOG performance status of 0-2
• Candidate for treatment with gemcitabine and nab-paclitaxel
• Able to operate the NovoTTF-200T system independently or with caregiver support

You may not qualify if:

• Prior palliative treatment to the pancreatic tumor
• Other active malignancies within the past 5 years (except certain early-stage cancers)
• Significant uncontrolled medical conditions or infections that would interfere with therapy
• Implantable electronic devices in the torso
• Known severe hypersensitivity to adhesives, hydrogel, or chemotherapy agents
• Pregnancy or breastfeeding

Sponsors & Collaborators

• NovoCure GmbH: lead

MeSH Terms

Interventions

Gemcitabine; Taxes

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Economics; Health Care Economics and Organizations

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2025
• First Posted: January 6, 2026
• Last Updated: January 6, 2026

Record last verified: 2025-12